Why the study?
Does bishydroxycoumarin reduce mortality or thromboembolic complications in patients with myocardial infarction?
Does bishydroxycoumarin reduce mortality or thromboembolic complications in patients with myocardial infarction?
Answers are grounded in this paper and cite their sources.
This letter clarifies that while bishydroxycoumarin did not reduce thromboembolic complications in myocardial infarction, there was a notable difference in mortality (10% treated vs 21.3% untreated).
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Laurent J. Feldman (1955) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: